vs
Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and Tonix Pharmaceuticals Holding Corp. (TNXP). Click either name above to swap in a different company.
Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $5.4M, roughly 1.4× Tonix Pharmaceuticals Holding Corp.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -870.3%, a 862.8% gap on every dollar of revenue. On growth, Tonix Pharmaceuticals Holding Corp. posted the faster year-over-year revenue change (108.8% vs -4.5%). Over the past eight quarters, Tonix Pharmaceuticals Holding Corp.'s revenue compounded faster (47.4% CAGR vs -1.5%).
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
MGLD vs TNXP — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.6M | $5.4M |
| Net Profit | $-576.0K | $-46.9M |
| Gross Margin | 74.0% | 80.4% |
| Operating Margin | -8.3% | -895.8% |
| Net Margin | -7.5% | -870.3% |
| Revenue YoY | -4.5% | 108.8% |
| Net Profit YoY | 67.0% | -112.2% |
| EPS (diluted) | $-0.01 | $-4.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.6M | $5.4M | ||
| Q3 25 | $7.0M | $3.3M | ||
| Q2 25 | $7.2M | $2.0M | ||
| Q1 25 | $7.0M | $2.4M | ||
| Q4 24 | $8.0M | $2.6M | ||
| Q3 24 | $7.9M | $2.8M | ||
| Q2 24 | $8.3M | $2.2M | ||
| Q1 24 | $7.9M | $2.5M |
| Q4 25 | $-576.0K | $-46.9M | ||
| Q3 25 | $-356.0K | $-32.0M | ||
| Q2 25 | $-1.5M | $-28.3M | ||
| Q1 25 | $-1.0M | $-16.8M | ||
| Q4 24 | $-1.7M | $-22.1M | ||
| Q3 24 | $-1.6M | $-14.2M | ||
| Q2 24 | $-1.9M | $-78.8M | ||
| Q1 24 | $-529.0K | $-14.9M |
| Q4 25 | 74.0% | 80.4% | ||
| Q3 25 | 77.0% | 58.4% | ||
| Q2 25 | 67.8% | -63.8% | ||
| Q1 25 | 75.0% | 61.2% | ||
| Q4 24 | 74.1% | 54.2% | ||
| Q3 24 | 73.1% | 44.9% | ||
| Q2 24 | 72.5% | -52.5% | ||
| Q1 24 | 70.5% | 33.1% |
| Q4 25 | -8.3% | -895.8% | ||
| Q3 25 | -18.2% | -1005.1% | ||
| Q2 25 | -16.5% | -1416.2% | ||
| Q1 25 | -21.4% | -660.9% | ||
| Q4 24 | -22.8% | -870.6% | ||
| Q3 24 | -27.4% | -551.2% | ||
| Q2 24 | -33.3% | -3501.6% | ||
| Q1 24 | -18.7% | -860.2% |
| Q4 25 | -7.5% | -870.3% | ||
| Q3 25 | -5.1% | -972.9% | ||
| Q2 25 | -20.4% | -1415.0% | ||
| Q1 25 | -14.4% | -692.8% | ||
| Q4 24 | -21.8% | -856.2% | ||
| Q3 24 | -20.1% | -503.6% | ||
| Q2 24 | -22.5% | -3567.8% | ||
| Q1 24 | -6.7% | -601.9% |
| Q4 25 | $-0.01 | $-4.28 | ||
| Q3 25 | $-0.01 | $-3.59 | ||
| Q2 25 | $-0.04 | $-3.86 | ||
| Q1 25 | $-0.02 | $-2.84 | ||
| Q4 24 | $-0.04 | $2302.65 | ||
| Q3 24 | $-0.04 | $-22.68 | ||
| Q2 24 | $-0.05 | $-1920.85 | ||
| Q1 24 | $-0.01 | $-535.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.6M | $207.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $22.7M | $245.2M |
| Total Assets | $27.8M | $277.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $207.6M | ||
| Q3 25 | $12.5M | $190.1M | ||
| Q2 25 | $12.8M | $125.3M | ||
| Q1 25 | $15.6M | $131.7M | ||
| Q4 24 | $14.9M | $98.8M | ||
| Q3 24 | $17.5M | $28.2M | ||
| Q2 24 | $15.0M | $4.2M | ||
| Q1 24 | $16.1M | $7.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $10.8M |
| Q4 25 | $22.7M | $245.2M | ||
| Q3 25 | $22.9M | $231.1M | ||
| Q2 25 | $23.0M | $168.0M | ||
| Q1 25 | $24.3M | $180.4M | ||
| Q4 24 | $23.4M | $139.6M | ||
| Q3 24 | $25.5M | $74.2M | ||
| Q2 24 | $26.6M | $42.1M | ||
| Q1 24 | $28.4M | $108.1M |
| Q4 25 | $27.8M | $277.2M | ||
| Q3 25 | $28.4M | $252.4M | ||
| Q2 25 | $30.4M | $187.4M | ||
| Q1 25 | $33.5M | $192.9M | ||
| Q4 24 | $33.0M | $162.9M | ||
| Q3 24 | $35.9M | $95.0M | ||
| Q2 24 | $32.9M | $70.3M | ||
| Q1 24 | $33.7M | $135.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.06× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-908.0K | $-39.6M |
| Free Cash FlowOCF − Capex | — | $-41.5M |
| FCF MarginFCF / Revenue | — | -770.4% |
| Capex IntensityCapex / Revenue | 0.0% | 34.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-103.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-908.0K | $-39.6M | ||
| Q3 25 | $-533.0K | $-28.8M | ||
| Q2 25 | $-3.3M | $-14.8M | ||
| Q1 25 | $-1.2M | $-16.6M | ||
| Q4 24 | $-770.0K | $-14.6M | ||
| Q3 24 | $-893.0K | $-18.8M | ||
| Q2 24 | $-1.9M | $-9.9M | ||
| Q1 24 | $-658.0K | $-17.6M |
| Q4 25 | — | $-41.5M | ||
| Q3 25 | $-562.0K | $-29.7M | ||
| Q2 25 | $-3.4M | $-15.4M | ||
| Q1 25 | — | $-16.6M | ||
| Q4 24 | $-776.0K | $-14.6M | ||
| Q3 24 | $-940.0K | $-18.8M | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | — | $-17.7M |
| Q4 25 | — | -770.4% | ||
| Q3 25 | -8.1% | -904.1% | ||
| Q2 25 | -46.8% | -768.8% | ||
| Q1 25 | — | -682.8% | ||
| Q4 24 | -9.7% | -566.7% | ||
| Q3 24 | -11.9% | -666.5% | ||
| Q2 24 | -23.8% | — | ||
| Q1 24 | — | -712.4% |
| Q4 25 | 0.0% | 34.8% | ||
| Q3 25 | 0.4% | 29.2% | ||
| Q2 25 | 0.7% | 26.4% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.6% | 0.3% | ||
| Q2 24 | 0.7% | 0.0% | ||
| Q1 24 | 0.0% | 4.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
TNXP
| Zembrace Symtouch | $3.1M | 58% |
| Other | $2.3M | 42% |
